Literature DB >> 9140449

Cytogenetic polyclonality in tumors of the breast.

S Heim1, M R Teixeira, C U Dietrich, N Pandis.   

Abstract

Cytogenetically unrelated clones are found in half of all carcinomas of the breast and also in the epithelial fraction of many benign breast tumors. The chromosomal aberrations thus detected are clearly nonrandom and appear to be the same as those often seen in other tumors as sole karyotypic anomalies. Clonal chromosome abnormalities are not found in histologically normal breast tissue. Cytogenetically unrelated clones may be found in both primary tumors and secondary lesions, be it within the same breast (multifocal carcinomas), in the contralateral breast (bilateral carcinomas), or in lymph node or other metastases. The aberrations are present in topologically separate tumor domains and may confer on the cells that harbor them different types of cancer-specific behavior, such as the ability to metastasize and invade locally. Whereas the available evidence thus strongly indicates that the cells carrying clonal karyotypic aberrations all are part of the neoplastic parenchyma, it is less certain whether cytogenetic polyclonality actually signifies a multicellular tumor origin, although we think that this is the explanation that best accommodates the cytogenetic data. But even if it should eventually be shown that the seemingly unrelated clones have some submicroscopic tumorigenic mutation in common, the observed karyotypic heterogeneity is remarkable and goes far beyond what one has become accustomed to from most other tumor types. To understand how the various clones interact during mammary carcinogenesis will be a major task in future breast cancer research.

Entities:  

Mesh:

Year:  1997        PMID: 9140449     DOI: 10.1016/s0165-4608(96)00322-6

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  13 in total

Review 1.  The clonal origin and clonal evolution of epithelial tumours.

Authors:  S B Garcia; M Novelli; N A Wright
Journal:  Int J Exp Pathol       Date:  2000-04       Impact factor: 1.925

Review 2.  Role of positron emission tomography for the monitoring of response to therapy in breast cancer.

Authors:  Olivier Humbert; Alexandre Cochet; Bruno Coudert; Alina Berriolo-Riedinger; Salim Kanoun; François Brunotte; Pierre Fumoleau
Journal:  Oncologist       Date:  2015-01-05

3.  Loss of heterozygosity analysis of microsatellites on multiple chromosome regions in dysplasia and squamous cell carcinoma of the esophagus.

Authors:  Ming Liu; Feng Zhang; Shen Liu; Wen Zhao; Jing Zhu; Xiaoli Zhang
Journal:  Exp Ther Med       Date:  2011-06-27       Impact factor: 2.447

4.  Breast cancer with brain metastases: clinicopathologic features, survival, and paired biomarker analysis.

Authors:  Qi Shen; Aysegul A Sahin; Kenneth R Hess; Dima Suki; Kenneth D Aldape; Raymond Sawaya; Nuhad K Ibrahim
Journal:  Oncologist       Date:  2015-03-23

5.  Inferring tumor progression from genomic heterogeneity.

Authors:  Nicholas Navin; Alexander Krasnitz; Linda Rodgers; Kerry Cook; Jennifer Meth; Jude Kendall; Michael Riggs; Yvonne Eberling; Jennifer Troge; Vladimir Grubor; Dan Levy; Pär Lundin; Susanne Månér; Anders Zetterberg; James Hicks; Michael Wigler
Journal:  Genome Res       Date:  2009-11-10       Impact factor: 9.043

6.  Hex1: a new human Rad2 nuclease family member with homology to yeast exonuclease 1.

Authors:  D M Wilson; J P Carney; M A Coleman; A W Adamson; M Christensen; J E Lamerdin
Journal:  Nucleic Acids Res       Date:  1998-08-15       Impact factor: 16.971

7.  Comparative study of the immunohistochemical detection of hormone receptor status and HER-2 expression in primary and paired recurrent/metastatic lesions of patients with breast cancer.

Authors:  Ebru Sari; Gulnur Guler; Mutlu Hayran; Ibrahim Gullu; Kadri Altundag; Yavuz Ozisik
Journal:  Med Oncol       Date:  2010-01-23       Impact factor: 3.064

8.  HER2-positive breast cancer: ¹⁸F-FDG PET for early prediction of response to trastuzumab plus taxane-based neoadjuvant chemotherapy.

Authors:  Olivier Humbert; Alexandre Cochet; Jean-Marc Riedinger; Alina Berriolo-Riedinger; Laurent Arnould; Bruno Coudert; Isabelle Desmoulins; Michel Toubeau; Inna Dygai-Cochet; Séverine Guiu; Charles Coutant; Pierre Fumoleau; François Brunotte
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-03-20       Impact factor: 9.236

9.  Microsatellite analysis in multistage carcinogenesis of esophageal squamous cell carcinoma from Chongqing in Southern China.

Authors:  Ming Liu; Feng Zhang; Shen Liu; Wen Zhao; Jing Zhu; Xiaoli Zhang
Journal:  Int J Mol Sci       Date:  2011-10-28       Impact factor: 5.923

10.  Cytogenetic and molecular genetic demonstration of polyclonality in an acinic cell carcinoma.

Authors:  C Jin; Y Jin; M Höglund; J Wennerberg; J Akervall; R Willén; M Dictor; N Mandahl; F Mitelman; F Mertens
Journal:  Br J Cancer       Date:  1998-08       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.